Ethical Perspectives of Therapeutic Human Genome Editing From Multiple and Diverse Viewpoints: A Scoping Review

Joseph, Andrew M; Karas, Monica; Ramadan, Yaseen; Joubran, Ernesto; Jacobs, Robin J.

doi:10.7759/cureus.31927

Cited by 3 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another significant barrier lying ahead of gene editing is the ethical dilemma. Every country and nation have variable beliefs and may have different approaches toward somatic changes in the human species that would originate from gene therapy [ 48 ]. There is a concern about whether this therapy can be used one day to enhance or favorably alter various human characteristics such as appearance, learning ability, memory function, or endurance tolerance.…”

Section: Reviewmentioning

confidence: 99%

The Use of CRISPR-Cas9 Genetic Technology in Cardiovascular Disease: A Comprehensive Review of Current Progress and Future Prospective

Asif,

Khan,

Aslam

et al. 2024

Cureus

View full text Add to dashboard Cite

Over the last century, there have been major landmark developments in the field of medicine, enabling us to control and cure various diseases on a larger scale. A few of these include the discovery of antibiotics, the development of vaccines, and the origin of organ and tissue transplants. The continued quest for innovation in microbiology and medicine has helped humankind save millions of lives and decrease morbidity at the global level. Genetic medicine has grown significantly in the last two decades and appears to be the next frontier of curative therapies for chronic diseases. One important landmark in genetic medicine is the development of CRISPR (clustered, regularly interspaced short palindromic repeats) technology. In this article, we describe the basic structure and function of the CRISPR-Cas9 system, which, simply put, consists of an RNA part and a protein. It works as a molecular scissor that can perform targeted cuts followed by repairs in and around the genes of interest to attain favorable translational outcomes. We focused on summarizing recent studies using CRISPR-Cas9 technology in diagnosing and treating cardiovascular disease. These studies are primarily experimental and limited to animal models. However, their results are promising enough to anticipate that this technology will undoubtedly be available in clinical medicine in the coming years. CRISPR-Cas9-mediated gene editing has been used to study and potentially treat congenital heart disease, hyperlipidemias, arrhythmogenic cardiomyopathies, and the prevention of ischemia-reperfusion injury. Despite the current progress, we recognize the several challenges this technology faces, including funding for research, improving precision and reproducible results for human subjects, and establishing protocols for ethical compliance so that it is acceptable to the scientific community and the general public.

show abstract

Section: Reviewmentioning

confidence: 99%

The Use of CRISPR-Cas9 Genetic Technology in Cardiovascular Disease: A Comprehensive Review of Current Progress and Future Prospective

Asif,

Khan,

Aslam

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Delving into the blueprint of life (DNA) and modifying it evokes profound ethical debates [102][103][104][105]:…”

Section: Ethical Considerations Of Enhanced Gene Editing and Stem Cel...mentioning

confidence: 99%

The Art of Nanoimmunobiotechnomedicine in Stem Cells and Gene Editing

Anurogo

2023

J Biomed Res Environ Sci

View full text Add to dashboard Cite

This comprehensive review provides an exploration of Nanoimmunobiotechnomedicine (NIBTM) within the arenas of stem cells and gene editing. Encompassing the interdisciplinary amalgamation of nanotechnology, immunology, biotechnology, and medicine, the study accentuates the transformative potential of NIBTM in therapeutic innovations. By delving deep into stem cell biology, gene editing intricacies, and nanotechnology applications, the study sheds light on the tools and methodologies that leverage nanoparticles for both stem cell research and gene editing. Real-world case studies are employed to underscore the pragmatic applications and the ensuing benefits. Additionally, the study addresses the ethical, safety, and regulatory aspects tied to this novel approach, offering a balanced view of its promise and challenges. Ultimately, the narrative charts the imminent evolution of NIBTM, underscoring the indispensable role of interdisciplinary collaborations in driving holistic solutions in contemporary medicine.

show abstract

Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease

Katz,

Ohad,

Putter

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

Myxomatous mitral valve disease (MMVD) stands out as the most prevalent acquired canine heart disease. Its occurrence can reach up to 40% in small breed dogs and escalates in geriatric canine populations. MMVD leads to thickening and incomplete coaptation of valve leaflets during systole, resulting in secondary mitral valve regurgitation. Serious complications may arise concurrently with the worsening of mitral valve regurgitation, including left-and right-sided congestive heart failure, and pulmonary hypertension (PH). Ultimately, the PH progression might contribute to the patient’s demise or to the owner’s decision of euthanasia. Most currently available FDA-approved therapies for PH are costly and aim to address the imbalance between vasoconstriction and vasodilation to restore endothelial cell function. However, none of these medications impact the molecular dysfunction of cells or impede the advancement of pulmonary vascular and right ventricular remodeling. Recent evidence has showcased successful gene therapy approaches in laboratory animal models of PH. In this manuscript, we summarize the latest advancements in gene therapy for the treatment of PH in animals. The manuscript incorporates original data showcasing sample presentations, along with non-invasive hemodynamic assessments. Our findings demonstrate that the use of metabolic gene therapy, combining synthetic adeno-associated virus with acid ceramidase, has the potential to significantly reduce the need for drug treatment and improve spontaneously occurring PH in dogs.

show abstract

Ethical Perspectives of Therapeutic Human Genome Editing From Multiple and Diverse Viewpoints: A Scoping Review

Cited by 3 publications

References 46 publications

The Use of CRISPR-Cas9 Genetic Technology in Cardiovascular Disease: A Comprehensive Review of Current Progress and Future Prospective

The Use of CRISPR-Cas9 Genetic Technology in Cardiovascular Disease: A Comprehensive Review of Current Progress and Future Prospective

The Art of Nanoimmunobiotechnomedicine in Stem Cells and Gene Editing

Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease

Contact Info

Product

Resources

About